On Thursday, Regencell Bioscience Limited (RGC.US) extended its pre-market rally, climbing nearly 20% after accumulating a staggering 157% gain over the preceding three trading days, with its current price at $62.94.

Catalyzing the movement, Elon Musk recently stated on social media that his brain-computer interface company, Neuralink, will commence "mass production" of its brain-computer interface devices starting in 2026.

Simultaneously, the company is advancing a highly streamlined, almost fully automated surgical procedure, with the most critical breakthrough being that the electrode threads in the device will pass directly through the dura mater without the need for its removal.

Domestically, on January 7th, eight departments including the Ministry of Industry and Information Technology jointly issued the "Implementation Opinions on the Special Action for 'Artificial Intelligence + Manufacturing'," explicitly proposing to accelerate the industrialization and commercialization process of new terminals like brain-computer interfaces (BCI).

Analysis indicates that, driven by the combined forces of technological breakthroughs, policy incentives, and global industry resonance, brain-computer interface technology is rapidly transitioning from a frontier scientific concept to a critical leap towards commercialization and industrialization.